GIM
KZR

Granahan Investment Management’s Kezar Life Sciences KZR Stock Holding History

Granahan Investment Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-190,618
Closed -$1.81M – 190
2023
Q4 		$1.81M Buy
190,618
+45,362
+31% +$399K 0.06% 162
2023
Q3 		$1.73M Sell
145,256
-44,646
-24% -$791K 0.06% 162
2023
Q2 		$4.65M Buy
189,902
+77,768
+69% +$2.02M 0.14% 136
2023
Q1 		$3.51M Buy
112,134
+43,096
+62% +$2.49M 0.11% 140
2022
Q4 		$4.86M Buy
69,038
+24,296
+54% +$1.8M 0.15% 133
2022
Q3 		$3.85M Buy
44,742
+17,126
+62% +$1.66M 0.13% 139
2022
Q2 		$2.28M Buy
27,616
+10,647
+63% +$939K 0.08% 155
2022
Q1 		$2.82M Buy
16,969
+5,343
+46% +$767K 0.07% 160
2021
Q4 		$1.94M Buy
+11,626
New +$1.31M 0.04% 177

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Granahan Investment Management's KZR Position: Q1 2024 in Review

Granahan Investment Management sold out of Kezar Life Sciences (KZR) in Q1 2024, closing a stake of 190,618 shares — an estimated $1.81M sold.

Granahan Investment Management first reported a position in KZR in Q4 2021 and held it in 9 quarters. The position peaked at $4.86M in Q4 2022. 85 funds tracked by Wall St. Rank hold KZR as of Q1 2024.

  • Granahan Investment Management reported no remaining Kezar Life Sciences position as of Q1 2024 after selling out during the quarter.
  • Granahan Investment Management sold 190,618 Kezar Life Sciences shares in Q1 2024, an estimated $1.81M.
  • Granahan Investment Management first reported a position in Kezar Life Sciences in Q4 2021 and held it in 9 quarters.
  • Granahan Investment Management's Kezar Life Sciences position peaked at $4.86M in Q4 2022.
  • 85 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2024.

Based on Granahan Investment Management's 13F filing for Q1 2024, filed 15 May 2024.